Products List

Walvax has successfully developed 7 licensed vaccines, including recently approved 13-valent Pneumococcal Conjugate Vaccine (PCV13-TT), one of the most difficult vaccines to develop in the world.


Walvax proactively promotes PQ application of its products, and is proceeding with PQ application of 5 products. In 3 to 5 years, Walvax's WHO-PQ will yield fruitful results, which brings its internationalization to a higher level.

Quick Links

Haemophilus Influenzae Type b Conjugate Vaccine

Prevention of invasive infections caused by Haemophilus Influenzae type b for infants and children 2 months through 5 years of age.

Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, adsorbed

Prevention of pertussis, diphtheria and tetanus for infants and children 3 months through 6 years of age.